Investigative Radiology最新文献

Objectives: This study aimed to investigate the association between the use of linear and macrocyclic gadolinium-based contrast agents (GBCAs) and the subsequent development of Parkinson disease (PD).

Methods: In this retrospective cohort study, data were extracted from the Korean National Health Insurance Service database, comprising 1,038,439 individuals. From this population, 175,125 adults aged 40 to 60 years with no history of brain disease were identified. All patients including 3835 who were administered GBCA at least once were monitored until 2022 for the onset of PD. Propensity score (PS) matching was employed to compare the incidence of PD between those exposed to GBCAs (either linear or macrocyclic) and those not exposed (no-GBCA group).

Results: The final cohort consisted of 1175 subjects exposed to linear GBCAs, 2334 exposed to macrocyclic GBCAs, and 171,616 unexposed to any GBCA (no-GBCA group). After PS matching, PD incidence was significantly higher in the linear GBCA group compared with the no-GBCA group (0.9% vs 0.0%, P = 0.002) and was also significantly higher in the macrocyclic GBCA group than in the no-GBCA group (0.5% vs 0.04%, P = 0.003). No significant difference in PD incidence was observed between the linear and macrocyclic GBCA groups.

Conclusions: Exposure to GBCAs was linked to an increased risk of developing PD in this large population-based study. The risk of PD did not differ significantly between linear and macrocyclic GBCAs.

Objectives: Carotid plaque vulnerability is a strong predictor of recurrent ipsilateral stroke, but differentiation of plaque components using conventional computed tomography (CT) is suboptimal. The aim of our study was to evaluate the ability of dual-energy CT (DECT) to characterize atherosclerotic carotid plaque components based on the effective atomic number and effective electron density using magnetic resonance imaging (MRI) and, where possible, histology as the reference standard.

Materials and methods: Patients with recent cerebral ischemia and a ≥2-mm carotid plaque underwent computed tomography angiography and MRI. A subgroup underwent carotid endarterectomy. Trained observers delineated plaque components on histology or MRI, independent of computed tomography angiography. DECT was coregistered with MRI and/or histology. Intraplaque hemorrhage (IPH), lipid-rich necrotic core (LRNC), fibrous tissue, and calcifications were delineated on DECT, and ρeff and Zeff values were determined in the derivation cohort (n = 55). Spatial separation of these components was evaluated in a ρeff-Zeff-cluster plot. Ranges that optimally differentiate plaque features were determined. For validation, plaque components were quantified in the validation cohort (n = 29) using these ρeff-Zeff ranges and literature-based Hounsfield unit (HU) ranges and correlated to MRI volumes.

Results: Eighty-four participants (68 ± 8 years; 55 male) were evaluated. In the derivation cohort, plaque components were well separated on the cluster plot, resulting in the following ranges: IPH:ρeff < 1.15, Zeff < 7.5, LRNC:ρeff < 1.15, Zeff:7.5-8.75, fibrous tissue:ρeff < 1.15, Zeff > 8.75, and calcifications: ρeff > 1.15, Zeff > 0. In the validation cohort, significant correlations were found between ρeff-Zeff-based and MRI plaque volumes for fibrous tissue (r = 0.69, P < 0.001), LRNC (r = 0.94, P < 0.001), IPH (r = 0.35, P = 0.03), and calcifications (r = 0.70, P < 0.001). Lower correlations were found between HU-based and MRI plaque volumes for fibrous tissue (r = 0.40, P = 0.02), LRNC (r = 0.86, P < 0.001), and calcifications (r = 0.47, P = 0.005), with no correlation for IPH (r = 0.02, P = 0.45).

Conclusions: We determined ρeff-Zeff ranges for plaque assessment. ρeff-Zeff-based volumes showed strong-to-very strong correlations with MRI for LRNC, fibrous tissue, and calcifications and a weak correlation for IPH. ρeff-Zeff-based volumes demonstrated superior agreement with MRI for all plaque components compared with HU-based volumes, highlighting the potential of DECT for the identification of patients with vulnerable plaques.

Objectives: The aim of this study was to investigate the occurrence of motion artifacts and image quality of brain magnetic resonance imaging (MRI) T1-weighted imaging applying 3D motion correction via the Scout Accelerated Motion Estimation and Reduction (SAMER) framework compared with conventional T1-weighted imaging at 1.5 T.

Materials and methods: A preliminary study involving 14 healthy volunteers assessed the impact of the SAMER framework on induced motion during 3 T MRI scans. Participants performed 3 different motion patterns: (1) step up, (2) controlled breathing, and (3) free motion. The patient study included 82 patients who required clinically indicated MRI scans. 3D T1-weighted images (MPRAGE) were acquired at 1.5 T. The MRI data were reconstructed using either regular product reconstruction (non-Moco) or the 3D motion correction SAMER framework (SAMER Moco), resulting in 145 image sequences. For the preliminary and the patient study, 3 experienced radiologists evaluated the image data using a 5-point Likert scale, focusing on overall image quality, artifact presence, diagnostic confidence, delineation of pathology, and image sharpness. Interrater agreement was assessed using Gwet's AC2, and an exploratory analysis (non-Moco vs SAMER Moco) was performed.

Results: Compared with non-Moco, the preliminary study demonstrated significant improvements across all imaging parameters and motion patterns with SAMER Moco (P < 0.001). Odds ratios favoring SAMER Moco were >999.999 for freedom of artifact and overall image quality (P < 0.0001). Excellent or good ratings for freedom of artifact were 52.4% with SAMER Moco, compared with 21.4% for non-Moco. Similarly, 66.7% of SAMER Moco images were rated excellent or good for overall image quality versus 21.4% for non-Moco. Multireader interrater agreement was excellent across all parameters.The patient study confirmed that SAMER Moco provided significantly superior image quality across all evaluated imaging parameters, particularly in the presence of motion (P < 0.001). Diagnostic confidence was rated as excellent or good in 95.1% of SAMER Moco cases, compared with 78.1% for non-Moco cases. Similarly, overall image quality was rated as excellent or good in 89.8% of SAMER Moco cases versus 65.9% for non-Moco cases. The odds ratios for diagnostic confidence and for overall image quality were 6.698 and 6.030, respectively, both favoring SAMER Moco (P < 0.0001). Multireader interrater agreement was excellent across all parameters.

Conclusions: The application of SAMER in T1-weighted imaging datasets is feasible in clinical routine and significantly increases image quality and diagnostic confidence in 1.5 T brain MRI by effectively reducing motion artifacts.

Introduction: Atherosclerosis is the underlying cause of multiple cardiovascular pathologies. The present-day clinical imaging modalities do not offer sufficient information on plaque composition or rupture risk. A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) is a strongly upregulated proteoglycan-cleaving enzyme that is specific to cardiovascular diseases, inter alia, atherosclerosis.

Materials and methods: Male apolipoprotein E-deficient mice received a high-fat diet for 2 (n = 11) or 4 months (n = 11). Additionally, a group (n = 11) receiving pravastatin by drinking water for 4 months alongside the high-fat diet was examined. The control group (n = 10) consisted of C57BL/6J mice on standard chow. Molecular magnetic resonance imaging was performed prior to and after administration of the gadolinium (Gd)-based ADAMTS4-specific probe, followed by ex vivo analyses of the aortic arch, brachiocephalic arteries, and carotid arteries. A P value <0.05 was considered to indicate a statistically significant difference.

Results: With advancing atherosclerosis, a significant increase in the contrast-to-noise ratio was measured after intravenous application of the probe (mean precontrast = 2.25; mean postcontrast = 11.47, P < 0.001 in the 4-month group). The pravastatin group presented decreased ADAMTS4 expression. A strong correlation between ADAMTS4 content measured via immunofluorescence staining and an increase in the contrast-to-noise ratio was detected (R2 = 0.69). Microdissection analysis revealed that ADAMTS4 gene expression in the plaque area was significantly greater than that in the arterial wall of a control mouse (P < 0.001). Laser ablation-inductively coupled plasma-mass spectrometry confirmed strong colocalization of areas positive for ADAMTS4 and Gd.

Conclusions: Magnetic resonance imaging using an ADAMTS4-specific agent is a promising method for characterizing atherosclerotic plaques and could improve plaque assessment in the diagnosis and treatment of atherosclerosis.

Objectives: Impaired image quality and long scan times frequently occur in respiratory-triggered sequences in liver magnetic resonance imaging (MRI). We evaluated the impact of an in-bore active breathing guidance (BG) application on image quality and scan time of respiratory-triggered T2-weighted (T2) and diffusion-weighted imaging (DWI) by comparing sequences with standard triggering (T2S and DWIS) and with BG (T2BG and DWIBG).

Materials and methods: In this prospective study, random patients with clinical indications for liver MRI underwent 3 T MRI with standard and BG acquisitions. The audiovisual BG application received the respiratory signal from the scanner, and animated breathing instructions were displayed using a mirror and screen behind the MRI bore. Prior to the DWIBG and T2BG acquisition, patients received a short video instruction about MRI with BG. Suitable parameters for desired breathing pattern for T2BG and DWIBG were set individually for each patient based on the patient's physical respiratory ability (ie, 4 seconds breathing followed by 4.5 seconds breath holding). Artifacts, sharpness, lesion conspicuity, and overall image quality were assessed using a Likert scale from 1 (nondiagnostic) to 5 (excellent). Scan time, apparent contrast-to-noise ratio, and apparent signal-to-noise ratio (aSNR) for all sequences were analyzed. Paired t test and Wilcoxon test were used for statistical analysis.

Results: Thirty-two patients (mean age: 55 ± 13 years, 13 female) were included. T2BG showed less artifacts (4.5 ± 0.7 vs 4.1 ± 0.8, P < 0.001) and better sharpness, lesion conspicuity, and overall image quality (eg, overall image quality 4.6 ± 0.7 vs 4.4 ± 0.7, P = 0.004) compared with T2S. DWIBG demonstrated improved image quality in all categories compared with DWIS (eg, overall image quality 4.5 ± 0.5 vs 4.3 ± 0.5, P = 0.005) and less artifacts (4.1 ± 0.5 vs 3.8 ± 0.7, P = 0.007). Scan times of T2BG (286 ± 23 vs 345 ± 68 seconds, P < 0.001) and DWIBG (160 ± 4 vs 252 ± 70 seconds, P < 0.001) were reduced by 17% and 37%, respectively. aSNR and apparent contrast-to-noise ratio (eg, aSNR: 23.45 ± 11.31 [T2BG] vs 25.84 ± 10.76 [T2S]; P = 0.079) were similar for both sequences for both approaches.

Conclusions: Active BG for respiratory-triggered liver T2w and DWI sequences led to significant reduction of breathing artifacts, improved image quality, and shorter scan time compared with standard acquisitions.

Objectives: The aim of this study was to assess the impact of an iterative metal artifact reduction (iMAR) algorithm combined with virtual monoenergetic images (VMIs) for artifact reduction in photon-counting detector computed tomography (PCDCT) during interventions.

Materials and methods: Using an abdominal phantom, we conducted evaluations on the efficacy of iMAR and VMIs for mitigating image artifacts during interventions on a PCDCT. Four different puncture devices were employed under 2 scan modes (QuantumSn at 100 kV, Quantumplus at 140 kV) to simulate various clinical scenarios. Image reconstructions were initially performed without iMAR and subsequently with iMAR settings. The latter was tested with 7 different metal presets for each case. Furthermore, iMAR-reconstructed images were paired with VMIs at energy levels of 70 keV, 110 keV, 150 keV, and 190 keV. Qualitative assessments were conducted to evaluate image quality, artifact expression, and the emergence of new artifacts using a Likert scale. Image quality was rated on a scale of 1 (nondiagnostic) to 5 (excellent), whereas artifact severity was rated from 0 (none) to 5 (massive). Preferences for specific iMAR presets were documented. Quantitative analysis involved calculating Hounsfield unit (HU) differences between artifact-rich and artifact-free tissues.

Results: Overall, 96 different scanning series were evaluated. The optimal combination for artifact reduction was found to be iMAR neurocoils with VMIs at 150 keV and 190 keV, showcasing the most substantial reduction in artifacts with a median rating of 1 (standard: 4). VMIs at higher keV levels, such as 190 keV, resulted in reduced image quality, as indicated by a median rating of 3 (compared with 70 keV with a median of 5). Newly emerged artifact expression related to reconstructions varied among intervention devices, with iMAR thoracic coils exhibiting the least extent of artifacts (median: 2) and iMAR neurocoils displaying the most pronounced artifacts (median: 4). Qualitative analysis favored the combination of iMAR neurocoils with VMIs at 70 keV, showcasing the best results. Conversely, quantitative analysis revealed that the combination of iMAR neurocoils with VMIs at 190 keV yielded the best results, with an average artifact expression of 20.06 HU (standard: 167.98 HU; P < 0.0001).

Conclusions: The study underscores a substantial reduction in artifacts associated with intervention devices during PCDCT scans through the synergistic application of VMI and iMAR techniques. Specifically, the combination of VMIs at 70 keV with iMAR neurocoils was preferred, leading to enhanced diagnostic assessability of surrounding tissues and target lesions. The study demonstrates the potential of iMAR and VMIs for PCDCT-guided interventions. These advancements could improve accuracy, safety, efficiency, and patient outcomes in clinical practice.

Objective: This systematic review and meta-analysis investigated the added value of DWI compared with the structured assessment of BI-RADS criteria using the Kaiser score.

Materials and methods: Articles published in English until May 2024 were included. Two independent reviewers extracted data on the characteristics of studies evaluating the added value of DWI to distinguish benign from malignant breast lesions compared with structured assessment of the BI-RADS criteria. Using bivariate random-effects models, the sensitivity and specificity were calculated. I2 statistics, Deek's funnel plot asymmetry test for publication bias, and meta-regression were applied for the data analysis.

Results: Five studies comprising 1005 malignant and 846 benign lesions were eligible for data synthesis. The pooled sensitivity and specificity estimates of structured BI-RADS assessment were 95.7% (95% confidence interval [CI], 92.6%-97.5%) and 68.7% (95% CI, 60.9%-75.6%), respectively. Adding DWI to the structured BI-RADS assessment achieved a pooled sensitivity of 94.4% (95% CI, 90.5%-96.7%) and a pooled specificity of 74.9% (95% CI, 68.8%-80.2%). Adding DWI to the structured BI-RADS assessment significantly changed neither the sensitivity ( P = 0.52) nor the specificity ( P = 0.20).

Conclusions: This systematic review and meta-analysis revealed only a limited, statistically nonsignificant added value of DWI compared with the structured assessment of BI-RADS criteria using the Kaiser score.

Abstract: Local ablation therapy, encompassing radiofrequency ablation (RFA), microwave ablation, and cryoablation, has emerged as a crucial strategy for managing small hepatocellular carcinomas (HCCs), complementing liver resection and transplantation. This review delves into the clinical significance of tumor size, location, and biology in guiding treatment decisions for HCCs undergoing local ablation therapy, with a focus on tumors smaller than 3 cm. Tumor size significantly influences treatment outcomes, with larger tumors associated with poorer local tumor control due to challenges in creating sufficient ablative margins and the likelihood of microvascular invasion and peritumoral satellite nodules. Advanced ablation techniques such as centripetal or no-touch RFA using multiple electrodes, cryoablation using multiple cryoprobes, and microwave ablation offer diverse options for HCC treatment. Notably, no-touch RFA demonstrates superior local tumor control compared with conventional RFA by achieving sufficient ablative margins, making it particularly promising for hepatic dome lesions or tumors with aggressive biology. Laparoscopic RFA proves beneficial for treating anterior subphrenic HCCs, whereas artificial pleural effusion-assisted RFA is effective for controlling posterior subphrenic HCCs. However, surgical resection generally offers better survival outcomes for periportal HCCs compared with RFA. Cryoablation exhibits a lower incidence of vascular or biliary complications than RFA for HCCs adjacent to perivascular or periductal regions. Additionally, aggressive tumor biology, such as microvascular invasion, can be predicted using magnetic resonance imaging findings and serum tumor markers. Aggressive HCC subtypes frequently exhibit Liver Imaging Reporting and Data System M features on magnetic resonance imaging, aiding in prognosis. A comprehensive understanding of tumor size, location, and biology is imperative for optimizing the benefits of local ablation therapy in managing HCCs.

Abstract: Bladder cancer (BC) is a significant global health concern, with over 500,000 new cases and 200,000 deaths annually, emphasizing the need for accurate staging and effective management. Traditional diagnostic techniques, such as cystoscopy and transurethral resection, are fundamental but have limitations in accurately assessing the depth of invasion. These limitations include the possibility of understaging and procedural variability, which can significantly impact treatment decisions. This review focuses on the role of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis and staging of BC, particularly emphasizing the Vesical Imaging-Reporting and Data System (VI-RADS) framework. By enhancing interpretive consistency and diagnostic accuracy, mpMRI and VI-RADS offer detailed visualization of tumor characteristics and depth of invasion, while reducing the need for more invasive traditional methods. These advancements not only improve staging accuracy but also enhance treatment planning, underscoring the importance of advanced imaging in evolving BC management and positively influencing patient outcomes.